top of page
Vaccinex logo in blue

News Releases

2026

2025

2024

2023

2026

April 29, 2026

Vaccinex Reports 2025 Annual Financial Results

2025

Dec 23, 2025

Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease

Dec 3, 2025

Vaccinex Provides Update on Biomarkers Associated with Response to Treatment of Early Stage AD with Pepinemab at CTAD (Clinical Trials on Alzheimer's Disease)

May 27, 2025

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting

Apr 21, 2025

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)

Mar 7, 2025

Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market

2024

Dec 17, 2024

Vaccinex Announces Receipt of Delisting Notification from Nasdaq

Nov 18, 2024

Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 7, 2024

Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC

Nov 5, 2024

Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting

Oct 31, 2024

Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain

Oct 24, 2024

Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024

Sep 18, 2024

Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds

Aug 14, 2024

Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership

Jul 31, 2024

Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease

Jul 17, 2024

Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024

JuN 6, 2024

Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease

May 15, 2024

Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 2, 2024

Vaccinex Reports 2023 Financial Results and Provides Corporate Update

Mar 27, 2024

Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Feb 21, 2024

Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology

Feb 15, 2024

Vaccinex, Inc. Announces Reverse Stock Split

Feb 7, 2024

Vaccinex Announces Pricing of $3.7 Million PIPE Financing

2023

Nov 13, 2023

Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Oct 26, 2023

Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases

Apr 3, 2023

Vaccinex Reports 2022 Financial Results and Provides Corporate Update of Continued Progress in
Neurology and Oncology Clinical Programs

Jan 9, 2023

Vaccinex Announces First Patient Dosed with Anti-CCR8 Antibody Licensed to Surface Oncology

bottom of page